Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
AssigneeThe Regents of the University of Colorado
InventorRobert C. DOEBELE
Life of this patent
Estimating the term…
Abstract
The present invention includes methods of treating or preventing HER-driven drug-resistant cancers. In certain embodiments, the cancer comprises lung cancer.
Claims22
A method of treating or preventing a HER-driven drug-resistant cancer in a subject in need thereof, the method comprising:
- (a) providing tumor cells of the subject;
- (b) detecting presence or absence of an EGFR exon 20 insertion mutation in the provided tumor cells;
- (c) predicting the subject as being likely to be responsive to treatment by (2E)-4-{[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino}-N,N-dimethyl-N-[(1-methyl-4-nitro-1H-imidazol-5-yl)methyl]-4-oxo-2-buten-1-ammonium bromide (Compound A) and/or (2E)-N-[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(dimethylamino)-2-butenamide) (Compound B), if the EGFR exon 20 insertion mutation is detected;
- and
- (d) administering a therapeutically effective amount of at least one compound selected from the group consisting of Compound A and Compound B, or a salt or a solvate thereof.
A method of treating a HER-driven drug-resistant cancer in a subject with cancer, where an EGFR exon 20 insertion mutation is detected in tumor cells of the subject, wherein the method comprises administering a therapeutically effective amount of at least one compound selected from the group consisting of Compound A and Compound B, or a salt or a solvate thereof.
A method of predicting the responsiveness of a subject with a HER-driven drug-resistant cancer to treatment with at least one compound selected from the group consisting of Compound A and Compound B, wherein the method comprises:
- (a) providing tumor cells of the subject;
- (b) detecting presence or absence of an EGFR exon 20 insertion mutation in the provided tumor cells of the subject;
- (c) predicting the subject as being likely to be responsive to a treatment with the at least one compound if the EGFR exon 20 insertion mutation is detected in the provided tumor cells of the subject.
A method of predicting the responsiveness of a subject with a HER-driven drug-resistant cancer to treatment with at least one compound selected from the group consisting of Compound A and Compound B, wherein the method comprises detecting presence or absence of an EGFR exon 20 insertion mutation in a sample of tumor cells from the subject;
- wherein the subject is likely to be responsive to the treatment with the at least one compound if the EGFR exon 20 insertion mutation is detected in the sample of tumor cells from the subject.
A method of identifying a subject with cancer who is likely to be responsive to treatment with at least one compound selected from the group consisting of Compound A and Compound B, wherein the method comprises:
- (a) providing tumor cells of the subject;
- (b) detecting presence or absence of an EGFR exon 20 insertion mutation in the provided tumor cells;
- (c) identifying the subject as being likely to be responsive to treatment with the at least one compound if the EGFR exon 20 insertion mutation is detected in the provided tumor cells.
Dependencies are inferred from the claim text.